Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer , in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4.
Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023 Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438 .